etoposide + mafosfamide

Cycle B is a specific chemotherapy combination regimen developed by Baylor College of Medicine for the treatment of brain tumors in infants (typically under 3 years of age). It is part of a multi-phase induction protocol that precedes conformal radiation. The regimen consists of oral etoposide administered daily for 21 days and intrathecal mafosfamide administered once weekly. Etoposide is a small molecule topoisomerase II inhibitor that induces DNA double-strand breaks, leading to cell cycle arrest and apoptosis. Mafosfamide is an oxazaphosphorine alkylating agent and a pre-activated derivative of cyclophosphamide; unlike its parent compound, it does not require hepatic activation, which allows for direct intrathecal administration to target leptomeningeal disease and central nervous system malignancies while minimizing systemic toxicity.

Other names

Baylor Cycle B regimenBaylor College of Medicine Cycle B